Genentech, Inc.
NEWS
At the ASH meeting in Atlanta this morning, AbbVie and Genentech unveiled stellar results of its Phase III combination trial of Venclexta and Rituxan to treat patients with relapsed or refractory CLL.
One of the most important points about Hemlibra’s approval, beyond its significant efficacy is the positive impact it will have one the quality of life for these hemophilia patients.
Patients who received Tecentriq and Avastin in addition to standard chemo showed a 38 percent reduction in the risk of the disease getting worse or death.
Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.
A look at the FDA’s long-awaited guidelines on how it will regulate regenerative medicine products, including stem cells.
Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents.
Genentech announced that its Phase III HAVEN 3 study of Hemlibra in adults and adolescents with hemophilia A without inhibitors to factor VIII had positive results.
Genentech scored two approvals from the FDA this week.
The drug will be used to prevent or reduce the frequency of bleeding episodes in certain patients.
JOBS
IN THE PRESS